DNA co-methylation analysis of lincRNAs across nine cancer types reveals novel potential epigenetic biomarkers in cancer

Epigenomics. 2019 Aug;11(10):1177-1190. doi: 10.2217/epi-2018-0138. Epub 2019 Jul 26.

Abstract

Aim: The potential functions and prognostic value of lincRNAs with co-methylation events are explored in 9 cancer types. Materials & methods: Here, we evaluated the co-methylation events in promoter and gene-body regions between two lincRNAs across 9 cancer types by constructing a systematic biological framework. Results: The co-methylation events in both promoter and gene-body regions tended to be highly cancer specific. Patient samples could be separated by tumor and normal types according to the eigengenes of universal co-methylation clusters. Functional enrichment results revealed the lincRNAs that brought promoter and gene-body co-methylation events that affected cancer progress through participating in different pathways and could serve as potential prognostic biomarkers. Conclusion: The study provides new insight into the epigenetic regulation in cancer and leads to a potential new direction for epigenetic biomarker discovery.

Keywords: co-methylation; lincRNAs; molecular signature; pan-cancer analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Case-Control Studies
  • DNA Methylation*
  • Epigenesis, Genetic*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Prognosis
  • Promoter Regions, Genetic
  • RNA, Long Noncoding / genetics*
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding